DEPARTMENT.FACULTY

photo
Prof. Sartaj Tabassum
  • DEPARTMENT_STAFF.QUALIFICATION

    Ph.D

  • DEPARTMENT_STAFF.DESIGNATION

    Professor

  • DEPARTMENT_STAFF.THRUST_AREA

    Inorganic and Bioinorganic Chemistry

  • DEPARTMENT_STAFF.ADDRESS

    Office : Department of Chemistry,Aligarh Muslim UniversityAligarh-202002 (UP)India Res: 29-Nishat Apartments ,Badarbagh ,Aligarh-202002(UP)India

  • DEPARTMENT_STAFF.MOBILE

    9358255791

  • DEPARTMENT_STAFF.EMAIL

    tsartaj62@yahoo.com

  • DEPARTMENT_STAFF.TIME_TABLE

    Time Table

Prof. Sartaj Tabassum is working as a Professor in the Department of Chemistry, Aligarh Muslim University, Aligarh. He was awarded a Senior Research Fellowship (1988), and Research Associateship (1991) by CSIR New Delhi. He was appointed as a lecturer in the department of chemistry, Aligarh Muslim University, in 1993. He has published 176 papers,  in the journals of international repute and has 4207 citations and an h-index is 36. He has presented his research work and delivered invited lectures at conferences/symposia. He is a life member of ICC, CRSI, ISCB, DNA Society of India, and American Nano Society. He has successfully guided 19 Ph.D. and 4 M.Phil students. He has successfully completed many research projects granted by TWAS, Italy, CSIR, New Delhi, DBT, Govt. of India. As a distinguished Scientist, Prof. Tabassum was awarded the Overseas Associateship award in 2005 by DBT, Govt of India. He has signed several MoU and joint research collaborati6ns with the University of Camerino UNICAM, Italy, USM Malaysia, and USTC Hefei, China. He has visited many countries for academic pursuit China, the USA, Italy, and King Saud University Riyad Saudi Arabia as a fellow, visiting professor, and for international conferences. Prof. Tabassum is working in the area of medicinal inorganic chemistry and his main focus is the design and synthesis of heterobimetallic complexes that have the potential to act as cancer chemotherapeutics. Three patents have been granted in India ( 01) and the US ( 02) in which he has claimed that the new drug will be very effective with minimal side effects and it will be available at a meager cost.